Back to Search
Start Over
Astaxanthin Reduces the Severity of Intestinal Damage in a Neonatal Rat Model of Necrotizing Enterocolitis.
- Source :
-
American journal of perinatology [Am J Perinatol] 2022 Dec; Vol. 39 (16), pp. 1820-1827. Date of Electronic Publication: 2021 Apr 14. - Publication Year :
- 2022
-
Abstract
- Objective: This study aimed to ascertain the effects of astaxanthin (ASX) in an experimental necrotizing enterocolitis (NEC) model using rat pups.<br />Study Design: Forty-two pups born from five Wistar albino rats were randomly divided into three groups as the control group, NEC + placebo (saline), and NEC + ASX. Pups in the NEC + ASX group were given 100 mg/kg/day oral ASX from day 1 to day 4 of the study. Saline of 2 mL/kg was given to the NEC + placebo group. Histopathological, immunohistochemical (caspase-3), and biochemical evaluations including the total antioxidant status (TAS), total oxidant status (TOS), superoxide dismutase (SOD), glutathione (GSH), lipid hydroperoxide (LPO), 8-hydroxydeoxyguanosine (8-OHdG), advanced oxidation protein products (AOPP), myeloperoxidase (MPO), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and nuclear factor erythroid 2-related factor 2 (Nfr-2) activities were all performed.<br />Results: A better survival rate and weight gain were demonstrated in the NEC + ASX group ( p < 0.05). In the histopathological evaluation, the severity of intestinal damage was significantly reduced in the NEC + ASX group, as well as decreased apoptosis (enzyme-linked immunosorbent assay [ELISA] for caspase-3; p = 0.001). The biochemical analyses of intestinal tissue TOS, oxidative stress index (OSI; TOS/TAS), IL-1β, LPO, 8-OHdG, AOPP, caspase-3 ( p < 0.001 for all), and TNF-α and MPO ( p = 0.001 for both parameters) levels were lower in the NEC + ASX group than in the NEC + placebo group. Nrf-2, TAS, GSH, and SOD levels were higher in the NEC + ASX group than in the NEC + placebo group ( p = 0.001, 0.001, <0.001, and 0.01, respectively).<br />Conclusion: ASX treatment has been shown to effectively reduce the severity of intestinal damage in NEC due to its antioxidant, anti-inflammatory, and antiapoptotic properties.<br />Key Points: · NEC causes extremely high morbidity and mortality, as well as many complications.. · We investigated the effectiveness of ASX in the experimental NEC model created in rat pups.. · First study examining the effect of ASX on the experimental NEC rat model..<br />Competing Interests: None declared.<br /> (Thieme. All rights reserved.)
- Subjects :
- Animals
Rats
Caspase 3 metabolism
Caspase 3 therapeutic use
Animals, Newborn
Antioxidants pharmacology
Antioxidants therapeutic use
Antioxidants metabolism
Tumor Necrosis Factor-alpha
Advanced Oxidation Protein Products therapeutic use
Rats, Wistar
Oxidants metabolism
Superoxide Dismutase metabolism
Superoxide Dismutase therapeutic use
Disease Models, Animal
Enterocolitis, Necrotizing drug therapy
Enterocolitis, Necrotizing prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1098-8785
- Volume :
- 39
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- American journal of perinatology
- Publication Type :
- Academic Journal
- Accession number :
- 33853144
- Full Text :
- https://doi.org/10.1055/s-0041-1727156